Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ferrous Fumarate→

Ferrous Fumarate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
141-01-5
Molecular formula
C4H2FeO4
Molecular weight
169.9 g/mol
Drug class
Iron replacementferrous (Fe2+) iron source
Mechanism of action
Ferrous iron is absorbed primarily in the duodenum and proximal jejunum through divalent metal transporter 1 (DMT1). Absorbed iron enters the circulating transferrin pool and is incorporated into haemoglobin, myoglobin and iron-dependent enzymes. Fumarate, sulfate, succinate and ascorbate salts deliver the same ferrous iron moiety; elemental iron content and formulation affect dosing and tolerability, not the core deficiency indication.
Indications / reported uses
  • Prevention and treatment of iron deficiency
  • Treatment of iron-deficiency anaemia, including in pregnancy where clinically appropriate; elemental iron dose and tolerability depend on the particular salt and formulation

Sources: NIH Office of Dietary Supplements — Iron fact sheet · NHS — Iron deficiency anaemia · UK product information for ferrous salts

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Iron replacement; ferrous (Fe2+) iron source

Mechanism of action

Ferrous iron is absorbed primarily in the duodenum and proximal jejunum through divalent metal transporter 1 (DMT1). Absorbed iron enters the circulating transferrin pool and is incorporated into haemoglobin, myoglobin and iron-dependent enzymes. Fumarate, sulfate, succinate and ascorbate salts deliver the same ferrous iron moiety; elemental iron content and formulation affect dosing and tolerability, not the core deficiency indication.

General use cases

  • Prevention and treatment of iron deficiency
  • Treatment of iron-deficiency anaemia, including in pregnancy where clinically appropriate; elemental iron dose and tolerability depend on the particular salt and formulation
Active moiety: ferrous iron (Fe2+) (Simple salt/counter-ion form; shares the same API pharmacology and general use cases.)

Ferrous iron is the nutritionally/pharmacologically relevant moiety; fumarate is the counter-ion. Elemental iron content, solubility and tolerability differ by salt, but these do not create a different iron-deficiency indication.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Ferrous Fumarate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ferrous Fumarate Permitted Daily Exposure (PDE) report (the Ferrous Fumarate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ferrous Fumarate Occupational Exposure Limit (OEL) report (the Ferrous Fumarate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.